Clinical Trials for Uterine Cancer

201907060

A Phase I Study of PD-1 Inhibition with TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer Phase I Principal Investigator Markovina, Stephanie Disease Site Corpus Uteri Learn more about this…

201908011

GOG 3031: [TESARO 4010-03-001] A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY) Phase III Principal Investigator Powell,…

201909052

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC# 776864) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Phase III Principal Investigator Thaker, Premal…

201910148

A Phase 2, Single Arm Study of Atezolizumab + Bevacizumab in women with advanced, recurrent or persistent endometrial cancer Phase II (Cancer Control) (Cancer Prevention) Principal Investigator McCourt, Carolyn Disease Site Corpus Uteri Learn more…

202003113

A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer Phase III Principal Investigator Thaker, Premal Disease Site Corpus Uteri…

202004237

De-escalated Conformal Radiation Expedited Sequentially with Chemotherapy for Endometrial Cancer (DeCRESCEndo) Phase N/A Principal Investigator Lin, Alexander Disease Site Corpus Uteri Learn more about this study at: clinicaltrials.gov

202005122

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors Phase I/II Principal Investigator Ward, Jeffrey Disease Site Breast; Cervix; Corpus Uteri; Ill-Defined Sites; Lip, Oral Cavity…

202008155

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) Phase II (Cancer Control) Principal Investigator…

202101091

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations Phase II (Cancer Control) Principal Investigator Thaker, Premal Disease…